Lumara Health is focused on advancing patient care. Recently acquired by AMAG Pharmaceuticals, a specialty pharmaceutical company based in Massachusetts, Lumara Health is delivering on its commitment to the women’s health community. Find out more about who we are and what we stand for.
Learn more about AMAG Pharmaceuticals.
Helping Patients Achieve Therapy Adherence
My Adherence Program by Lumara Health is an over-the-phone program offered at no cost and designed to encourage adherence with treatment. The program connects eligible patients to dedicated nursing specialists to help increase compliance through weekly calls and educational health information.
Please view the step-by-step instructional prenatal yoga video above.
A commitment to the fight against prematurity
In the United States, one in nine
babies is born too early (<37 weeks gestation).¹ We believe that even one baby born too early is too many. There is still work to be done to lower the number of premature births. We are dedicated to doing our part in reducing the prematurity rate through collaboration with healthcare providers to advance patient care, research and development, and collaborative community educational initiatives.
Lumara Health Sponsors 40 Weeks Documentary
Lumara Health is proud to sponsor the pregnancy documentary, 40 Weeks. Created by an award-winning documentary team, the unscripted film documents the week-by-week journey of expecting mothers and their families. The film answers pregnancy-related questions through experiences of real women and medical experts, including the importance of a full-term pregnancy. Learn more about the 40 Weeks documentary and Lumara Health’s involvement.
A FOCUS ON QUALITY
As part of AMAG Pharmaceuticals, we are passionate about the need to deliver quality products to patients and healthcare providers. FDA-approved products provide patients the confidence that they are receiving high-quality, safe, and effective treatments.
Making A Meaningful Difference
For Our Patients
Every week of pregnancy matters – each week the baby is reaching important developmental milestones. Learn about the risk factors for preterm birth and view two patient stories in this video segment from The Balancing Act®.
For more patient stories, click here.
New! LUMARA HEALTH ANNOUNCES RESEARCH GRANTS TO ADDRESS PREMATURITY
We recognize that a number of clinicians and researchers are interested in studying preterm birth to better understand risk factors and interventions to reduce preterm birth. For the third year, we are pleased to support research aimed at reducing preterm birth rates and associated complications. A total of $300,000 will be awarded by an external panel of judges for research in this arena. Interested applicants should click here to complete their submission. All applications must be received by July 31, 2016 to be eligible for evaluation.
Lumara Health Announcements
AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena®
April 4, 2016
AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena®
February 23, 2016
AMAG Pharmaceuticals to Acquire Cord Blood Registry
June 29, 2015
AMAG Pharmaceuticals Launches Initiative to Raise Awareness of Preterm Birth and the Importance of a Full-Term Pregnancy
June 9, 2015
AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth
May 20, 2015
AMAG Pharmaceuticals Completes Acquisition of Lumara Health’s Maternal Health Business
November 12, 2014
Lumara Health™ to Sponsor 40 Weeks Documentary to Raise Awareness of the Importance of a Full-Term Pregnancy
November 6, 2014
Lumara Health™ Announces Recipients of $75,000 in Grants to Fund Prematurity Prevention Research
October 28, 2014